Chong Kun Dang Pharmaceutical (XKRX:185750) COGS-to-Revenue : 0.63 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical COGS-to-Revenue?

Chong Kun Dang Pharmaceutical's Cost of Goods Sold for the three months ended in Mar. 2024 was ₩228,972 Mil. Its Revenue for the three months ended in Mar. 2024 was ₩361,502 Mil.

Chong Kun Dang Pharmaceutical's COGS to Revenue for the three months ended in Mar. 2024 was 0.63.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Chong Kun Dang Pharmaceutical's Gross Margin % for the three months ended in Mar. 2024 was 36.66%.

Chong Kun Dang Pharmaceutical COGS-to-Revenue Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical COGS-to-Revenue Chart

Chong Kun Dang Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.63

0.62

0.63

0.64

0.60

Chong Kun Dang Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.63	0.64	0.63	0.54	0.63

Chong Kun Dang Pharmaceutical COGS-to-Revenue Calculation

Chong Kun Dang Pharmaceutical's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1007202.93	/	1669404.439
	=	0.60

Chong Kun Dang Pharmaceutical's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	228972.253	/	361502.276
	=	0.63

Chong Kun Dang Pharmaceutical (XKRX:185750) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Chong Kun Dang Pharmaceutical's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	228972.253 / 361502.276
	=	36.66 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Chong Kun Dang Pharmaceutical COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756

Website

http://chongkundang.en.ec21.com

Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines